Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference
Salarius Pharmaceuticals (Nasdaq: SLRX) announced participation in the Benchmark Company Discovery One-on-One Investor Conference on December 2, 2021. CEO David Arthur and the management team will engage in one-on-one meetings with registered investors to discuss the company’s business highlights, recent achievements, and upcoming clinical milestones. Salarius is focused on developing novel therapies for cancers, particularly its lead candidate, seclidemstat, which is in clinical trials for Ewing sarcoma and related cancers.
- None.
- None.
HOUSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid cancers, announced today that its chief executive officer, David Arthur, and other members of the Company’s management team will participate in the Benchmark Company Discovery One-on-One Investor Conference. The conference is taking place via an all-virtual platform on Thursday, December 2, 2021.
Mr. Arthur and members of the Salarius management team will host one-on-one meetings with investors registered for the conference to discuss Salarius’ business, recent achievements, and anticipated clinical milestones.
Details for the conference are as follows:
| Event: | The Benchmark Company Discovery One-on-One Investor Conference |
| Date: | Thursday, December 2, 2021 |
| Time: | 9:00 a.m. ET to 4:00 p.m. ET |
| Registration: | https://www.meetmax.com/sched/event_78191/entity_login.html?attendee_role_id=COMPANY&event_id=78191&username=Salarius |
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius’ lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and select additional sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also exploring seclidemstat’s potential in several cancers with high unmet medical need, with a second Phase 1/2 clinical study initiated by MD Anderson Cancer Center in hematologic cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.
Contact
Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA (Investors)
(212) 375-2664
mmcenroe@tiberend.com
Johanna Bennett (Media)
(212) 375-2686
jbennett@tiberend.com
FAQ
What is the date of the Benchmark Company Discovery One-on-One Investor Conference involving SLRX?
Who will represent SLRX at the Benchmark Company conference?
What will SLRX discuss during the investor conference?
What is the primary focus of Salarius Pharmaceuticals (SLRX)?
What is seclidemstat and its significance for Salarius Pharmaceuticals (SLRX)?
